RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.